Connected profiles1
Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Heart Failure With Preserved Ejection Fraction peptide trials
1 selected ClinicalTrials.gov records carrying the official condition label Heart Failure With Preserved Ejection Fraction. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
1 selected records.
Connected peptides
1 profiles.
Registry update years
2026–2026 in selected records.
Indication intelligence
Selected evidence landscape
Trial phases1
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 3 (1)
Registry statuses1
Overall statuses at each retained observation, not necessarily current today.
Recruiting (1)
Across the connected peptide profiles, PeptideScanner also carries 4 selected PubMed records and 0 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Heart Failure With Preserved Ejection Fraction unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT07037459
PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- July 2, 2026
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Maridebart cafraglutide · 2026-07-02
ClinicalTrials.gov record NCT07037459
Recruiting at the retained observation.
Open attributed record →